Mayne Pharma Group Stock Fundamentals
| MAYNF Stock | USD 3.10 0.10 3.33% |
Mayne Pharma Group fundamentals help investors to digest information that contributes to Mayne Pharma's financial success or failures. It also enables traders to predict the movement of Mayne Pink Sheet. The fundamental analysis module provides a way to measure Mayne Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mayne Pharma pink sheet.
Mayne |
Mayne Pharma Group Company Return On Asset Analysis
Mayne Pharma's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Mayne Pharma Return On Asset | -0.0328 |
Most of Mayne Pharma's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mayne Pharma Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Mayne Pharma Group has a Return On Asset of -0.0328. This is 99.63% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—General industry. The return on asset for all United States stocks is 76.57% lower than that of the firm.
Mayne Pharma Group Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mayne Pharma's current stock value. Our valuation model uses many indicators to compare Mayne Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mayne Pharma competition to find correlations between indicators driving Mayne Pharma's intrinsic value. More Info.Mayne Pharma Group is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mayne Pharma's earnings, one of the primary drivers of an investment's value.Mayne Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mayne Pharma's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Mayne Pharma could also be used in its relative valuation, which is a method of valuing Mayne Pharma by comparing valuation metrics of similar companies.Mayne Pharma is currently under evaluation in return on asset category among its peers.
Mayne Fundamentals
| Return On Equity | -0.41 | |||
| Return On Asset | -0.0328 | |||
| Profit Margin | (0.62) % | |||
| Operating Margin | (0.17) % | |||
| Current Valuation | 448.85 M | |||
| Shares Outstanding | 1.74 B | |||
| Shares Owned By Insiders | 22.62 % | |||
| Shares Owned By Institutions | 18.64 % | |||
| Price To Earning | 11.25 X | |||
| Price To Book | 0.73 X | |||
| Price To Sales | 0.65 X | |||
| Revenue | 423.92 M | |||
| Gross Profit | 171.03 M | |||
| EBITDA | (104.64 M) | |||
| Net Income | (263.34 M) | |||
| Cash And Equivalents | 98.01 M | |||
| Cash Per Share | 0.06 X | |||
| Total Debt | 413.67 M | |||
| Debt To Equity | 0.74 % | |||
| Current Ratio | 0.84 X | |||
| Book Value Per Share | 0.32 X | |||
| Cash Flow From Operations | (7.21 M) | |||
| Earnings Per Share | (0.03) X | |||
| Number Of Employees | 31 | |||
| Beta | 1.0 | |||
| Market Capitalization | 235.41 M | |||
| Total Asset | 1.29 B | |||
| Annual Yield | 0.20 % | |||
| Net Asset | 1.29 B |
About Mayne Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mayne Pharma Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mayne Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mayne Pharma Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia. Mayne Pharma operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in Mayne Pink Sheet
Mayne Pharma financial ratios help investors to determine whether Mayne Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mayne with respect to the benefits of owning Mayne Pharma security.